CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro

The goal of targeted immunotherapy in cancer is to damage both malignant and tumor-supporting cells of the microenvironment but spare unaffected tissue. The malignant cells in classical Hodgkin lymphoma (cHL) selectively express CD30. They release this receptor on extracellular vesicles (EVs) for th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Hansen, Hinrich P., Trad, Ahmad, Dams, Maria, Zigrino, Paola, Moss, Marcia, Tator, Maximilian, Schön, Gisela, Grenzi, Patricia C, Bachurski, Daniel, Aquino, Bruno, Dürkop, Horst, Reiners, Katrin S, von Bergwelt-Baildon, Michael, Hallek, Michael, Grötzinger, Joachim, Engert, Andreas, Leme, Adriana F Paes, von Strandmann, Elke Pogge
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5058698/
https://ncbi.nlm.nih.gov/pubmed/27105521
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8864
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados